Lotus Pharmaceutical Co Ltd (TW:1795) — Market Cap & Net Worth
Market Cap & Net Worth: Lotus Pharmaceutical Co Ltd (1795)
Lotus Pharmaceutical Co Ltd (TW:1795) has a market capitalization of $1.45 Billion (NT$45.99 Billion) as of August 1, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #7227 globally and #215 in its home market, demonstrating a -7.16% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lotus Pharmaceutical Co Ltd's stock price NT$175.00 by its total outstanding shares 262809812 (262.81 Million). See 1795 capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Lotus Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Lotus Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $565.28 Million to $1.45 Billion (8.63% CAGR).
Lotus Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lotus Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.11x
Lotus Pharmaceutical Co Ltd's market cap is 0.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.50x
Lotus Pharmaceutical Co Ltd's market cap is 0.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $487.20 Million | $5.90 Billion | -$134.04 Million | 0.08x | N/A |
| 2017 | $414.81 Million | $6.42 Billion | $7.68 Million | 0.06x | 53.98x |
| 2018 | $602.69 Million | $6.43 Billion | $99.48 Million | 0.09x | 6.06x |
| 2019 | $935.35 Million | $9.17 Billion | $662.81 Million | 0.10x | 1.41x |
| 2020 | $650.68 Million | $10.73 Billion | $1.03 Billion | 0.06x | 0.63x |
| 2021 | $795.62 Million | $12.65 Billion | $1.40 Billion | 0.06x | 0.57x |
| 2022 | $2.04 Billion | $14.63 Billion | $3.02 Billion | 0.14x | 0.67x |
| 2023 | $2.25 Billion | $16.96 Billion | $4.11 Billion | 0.13x | 0.55x |
| 2024 | $2.23 Billion | $18.58 Billion | $5.07 Billion | 0.12x | 0.44x |
| 2025 | $2.34 Billion | $20.51 Billion | $4.72 Billion | 0.11x | 0.50x |
Competitor Companies of 1795 by Market Capitalization
Companies near Lotus Pharmaceutical Co Ltd in the global market cap rankings as of August 1, 2026.
Key companies related to Lotus Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
Lotus Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Lotus Pharmaceutical Co Ltd's market cap moved from $565.28 Million to $ 1.45 Billion, with a yearly change of 8.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$1.45 Billion | -38.16% |
| 2025 | NT$2.34 Billion | +5.01% |
| 2024 | NT$2.23 Billion | -0.92% |
| 2023 | NT$2.25 Billion | +10.57% |
| 2022 | NT$2.04 Billion | +156.01% |
| 2021 | NT$795.62 Million | +22.28% |
| 2020 | NT$650.68 Million | -30.43% |
| 2019 | NT$935.35 Million | +55.20% |
| 2018 | NT$602.69 Million | +45.29% |
| 2017 | NT$414.81 Million | -14.86% |
| 2016 | NT$487.20 Million | -13.81% |
| 2015 | NT$565.28 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Lotus Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.45 Billion USD |
| MoneyControl | $1.45 Billion USD |
| MarketWatch | $1.45 Billion USD |
| marketcap.company | $1.45 Billion USD |
| Reuters | $1.45 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lotus Pharmaceutical Co Ltd
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines;… Read more